MicroRNA‑373 exerts anti‑tumor functions in human liver cancer by targeting Rab22a

Ye,Ying; Zhang,Lijun; Song,Yanan; Zhuang,Juhua; Wang,Guoyu; Ni,Jing; Zhang,Suiliang; Xia,Wei

doi:10.3892/mmr.2019.10600

MicroRNA‑373 exerts anti‑tumor functions in human liver cancer by targeting Rab22a

Authors:
- Ying Ye
- Lijun Zhang
- Yanan Song
- Juhua Zhuang
- Guoyu Wang
- Jing Ni
- Suiliang Zhang
- Wei Xia
View Affiliations

Affiliations: Department of Nuclear Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China, Department of Oncology, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
Published online on: August 21, 2019 https://doi.org/10.3892/mmr.2019.10600
Pages: 3874-3882

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer is a one of the most frequent types of tumor worldwide. It has long been recognized that microRNAs are important participants in the progression of various types of cancer. The present study explored the role of microRNA‑373 (miR‑373) in liver cancer development. Reverse transcription‑quantitative polymerase chain reaction was performed to evaluate the transcription level of miR‑373 in 96 liver cancer tissues and adjacent normal liver tissues. The association of miR‑373 with clinicopathological characteristics was analyzed using the χ2 test. Kaplan‑Meier univariate analysis and multivariate hazard analysis were performed to identify the clinical potential of miR‑373 in the prognosis of liver cancer patients. Transfection of miR‑373 mimics into Hep3B and HepG2 liver cancer cell lines was conducted to reveal the underlying mechanism in regulating liver cancer progression. The functional assays included proliferation, migration, invasion and luciferase assays. The findings of the present study demonstrated that miR‑373 transcription level was markedly downregulated in liver cancer tissues compared with the adjacent normal tissues and was associated with the clinical prognosis of liver cancer patients. Overexpressing miR‑373 mimics in liver cancer cell lines decreased cell proliferation and invasion, suggesting that miR‑373 exerts anti‑tumor effects in liver cancer. In addition, data from the present study demonstrated the direct effect of miR373 on inhibiting the expression and signaling of Ras‑related protein Rab22a, a well‑known oncoprotein. Taken together, the results from the present study suggested that miR‑373 suppresses liver cancer progression and may serve as a promising prognosis prediction biomarker.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2:533–543. 2001. View Article : Google Scholar : PubMed/NCBI
3	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
4	Bruix J and Sherman M; Practice Guidelines Committee, : American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
5	Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Park HS, Lee WJ, Park SJ, Hong EK and Kim CM: Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol. 23:467–473. 2008. View Article : Google Scholar : PubMed/NCBI
6	Llovet JM, Fuster J and Bruix J; Barcelona-Clínic Liver Cancer Group, : The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 10 (Suppl 1):S115–S120. 2004. View Article : Google Scholar : PubMed/NCBI
7	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
8	Zhou W, Li Y, Gou S, Xiong J, Wu H, Wang C, Yan H and Liu T: miR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway. Oncotarget. 6:37557–37569. 2015. View Article : Google Scholar : PubMed/NCBI
9	Sun Y, Bai Y, Zhang F, Wang Y, Guo Y and Guo L: miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun. 391:1483–1489. 2010. View Article : Google Scholar : PubMed/NCBI
10	Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY and Zhuang SM: MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology. 54:1729–1740. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology. 58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
12	Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
13	Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, et al: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol. 604:17–46. 2007. View Article : Google Scholar : PubMed/NCBI
14	Jing SY, Jing SQ, Liu LL, Xu LF, Zhang F and Gao JL: Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target. Eur Rev Med Pharmacol Sci. 21:2421–2425. 2017.PubMed/NCBI
15	Zhang Q, Wang C, Miao S, Li C, Chen Z and Li F: Enhancing E-cadherin expression via promoter-targeted miR-373 suppresses bladder cancer cells growth and metastasis. Oncotarget. 8:93969–93983. 2017.PubMed/NCBI
16	Ding W, Fan XL, Xu X, Huang JZ, Xu SH, Geng Q, Li R, Chen D and Yan GR: Epigenetic silencing of ITGA2 by miR-373 promotes cell migration in breast cancer. PLoS One. 10:e01351282015. View Article : Google Scholar : PubMed/NCBI
17	Martins-Filho SN, Paiva C, Azevedo RS and Alves VAF: Histological grading of hepatocellular carcinoma - a systematic review of literature. Front Med (Lausanne). 4:1932017. View Article : Google Scholar : PubMed/NCBI
18	Zhou D, Li Z and Bai X: BRAFV600E and RET/PTC promote proliferation and migration of papillary thyroid carcinoma cells in vitro by regulating nuclear factor-κB. Med Sci Monit. 23:5321–5329. 2017. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Liu H, Zhang Q, Li K, Gong Z, Liu Z, Xu Y, Swaney MH, Xiao K and Chen Y: Prognostic significance of USP33 in advanced colorectal cancer patients: New insights into β-arrestin-dependent ERK signaling. Oncotarget. 7:81223–81240. 2016. View Article : Google Scholar : PubMed/NCBI
21	Carter P: Site-directed mutagenesis. Biochem J. 237:1–7. 1986. View Article : Google Scholar : PubMed/NCBI
22	Liu H, Xu Y, Zhang Q, Li K, Wang D, Li S, Ning S, Yang H, Shi W, Liu Z and Chen Y: Correlations between TBL1XR1 and recurrence of colorectal cancer. Sci Rep. 7:442752017. View Article : Google Scholar : PubMed/NCBI
23	Liu H, Liu Z, Li K, Li S, Song L, Gong Z, Shi W, Yang H, Xu Y, Ning S, et al: TBL1XR1 predicts isolated tumor cells and micrometastasis in patients with TNM stage I/II colorectal cancer. J Gastroenterol Hepatol. 32:1570–1580. 2017. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Zhao FJ, Chen LL, Wang LQ, Nephew KP, Wu YL and Zhang S: miR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget. 5:12291–12301. 2014.PubMed/NCBI
25	Wei F, Cao C, Xu X and Wang J: Diverse functions of miR-373 in cancer. J Transl Med. 13:1622015. View Article : Google Scholar : PubMed/NCBI
26	Baranwal S and Alahari SK: miRNA control of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290. 2010.PubMed/NCBI
27	Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A, et al: MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene. 31:4150–4163. 2012. View Article : Google Scholar : PubMed/NCBI
28	Chen Y, Luo J, Tian R, Sun H and Zou S: miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma. Dig Dis Sci. 56:1693–1701. 2011. View Article : Google Scholar : PubMed/NCBI
29	Wang LQ, Zhang Y, Yan H, Liu KJ and Zhang S: MicroRNA-373 functions as an oncogene and targets YOD1 gene in cervical cancer. Biochem Biophys Res Commun. 459:515–520. 2015. View Article : Google Scholar : PubMed/NCBI
30	Chen D, Dang BL, Huang JZ, Chen M, Wu D, Xu ML, Li R and Yan GR: miR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1alpha-TWIST signaling axis in breast cancer. Oncotarget. 6:32701–32712. 2015.PubMed/NCBI
31	Lu S, Zhu Q, Zhang Y, Song W, Wilson MJ and Liu P: Dual-functions of miR-373 and miR-520c by differently regulating the activities of MMP2 and MMP9. J Cell Physiol. 230:1862–1870. 2015. View Article : Google Scholar : PubMed/NCBI
32	Wu N, Liu X, Xu X, Fan X, Liu M, Li X, Zhong Q and Tang H: MicroRNA-373, a new regulator of protein phosphatase 6, functions as an oncogene in hepatocellular carcinoma. FEBS J. 278:2044–2054. 2011. View Article : Google Scholar : PubMed/NCBI
33	Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, et al: Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 18:3658–3667. 2012. View Article : Google Scholar : PubMed/NCBI
34	Wu X, Liu T, Fang O, Dong W, Zhang F, Leach L, Hu X and Luo Z: MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer. Oncotarget. 7:2417–2432. 2016.PubMed/NCBI
35	Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP and Odenthal M: MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 47:1223–1232. 2008. View Article : Google Scholar : PubMed/NCBI
36	Guo H, Liu H, Mitchelson K, Rao H, Luo M, Xie L, Sun Y, Zhang L, Lu Y, Liu R, et al: MicroRNAs-372/373 promote the expression of hepatitis B virus through the targeting of nuclear factor I/B. Hepatology. 54:808–819. 2011. View Article : Google Scholar : PubMed/NCBI
37	Mukherjee A, Di Bisceglie AM and Ray RB: Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway. J Virol. 89:3356–3365. 2015. View Article : Google Scholar : PubMed/NCBI
38	Cairo S, Wang Y, de Reyniès A, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM and Buendia MA: Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci USA. 107:20471–20476. 2010. View Article : Google Scholar : PubMed/NCBI